# KSQ-001EX

Source: https://onco.cc/drugs/ksq-001ex/  
OnCo record `ksq-001ex` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KSQ-001EX is an experimental engineered immune-cell therapy from KSQ Therapeutics, in phase 1 trials for melanoma, lung cancer and head and neck cancer.

## Summary

KSQ-001EX is an autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy from KSQ Therapeutics. Tumour-infiltrating lymphocytes with the SOCS1 gene switched off by CRISPR/Cas9, which the company says improves their anti-tumour activity, engraftment and persistence. Its phase 1/2 study (NCT06237881) is active but not recruiting; the company presented first-in-human phase 1 results at AACR in April 2026. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: KSQ-001EX
- Modality: Autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy
- Mechanism: Tumour-infiltrating lymphocytes with the SOCS1 gene switched off by CRISPR/Cas9, which the company says improves their anti-tumour activity, engraftment and persistence.

## Sources

- KSQ Therapeutics pipeline: https://ksqtx.com/pipeline/
- ClinicalTrials.gov NCT06237881: https://clinicaltrials.gov/study/NCT06237881

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [SOCS1](https://onco.cc/targets/socs1/)
- companies: [KSQ Therapeutics](https://onco.cc/companies/ksq-therapeutics/)
- trials: [A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors](https://onco.cc/trials/nct06237881/)

---
JSON: https://onco.cc/api/v1/entities/ksq-001ex.json